The oxytocin market is expected to grow at a compound annual growth rate of 5.46% over the forecast period to reach a market size of US$36.628 million in 2026 from US$25.242 million in 2019.
Oxytocin is produced in the hypothalamus and is secreted into the bloodstream by the posterior pituitary gland. Secretion depends on the electrical activity of neurons in the hypothalamus – it is released into the blood when these cells are excited. The two main actions of oxytocin in the body are contraction of the womb (uterus) during childbirth and lactation. The hormone is produced in the hypothalamus and is secreted from the paraventricular nucleus to the posterior pituitary where it is stored. It is then released in pulses during childbirth to induce uterine contractions. The concentration of oxytocin receptors on the myometrium increases significantly during pregnancy and reaches a peak in early labor. Activation of oxytocin receptors on the myometrium triggers a downstream cascade that leads to increased intracellular calcium in uterine myofibrils which strengthens and increases the frequency of uterine contractions. In humans, most hormones are regulated by negative feedback; however, oxytocin is one of the few that is regulated by positive feedback. The head of the fetus pushing on the cervix signals the release of oxytocin from the posterior pituitary of the mother. Oxytocin then travels to the uterus where it stimulates uterine contractions. The elicited uterine contractions will then stimulate the release of increasing amounts of oxytocin. This positive feedback loop will continue until parturition.
Since exogenously administered and endogenously secreted oxytocin result in the same effects on the female reproductive system, synthetic oxytocin may be used in specific instances during the antepartum and postpartum period to induce or improve uterine contractions. Oxytocin stimulates the uterine muscles to contract and also increases the production of prostaglandins, which increase the contractions further. Manufactured oxytocin is sometimes given to induce labor if it has not started naturally or it can be used to strengthen contractions to aid childbirth. In addition, manufactured oxytocin is often given to speed up delivery of the placenta and reduce the risk of heavy bleeding by contracting the uterus. During breastfeeding, oxytocin promotes the movement of milk through the ducts in the breast, allowing it to be excreted by the nipple. Oxytocin is also present in men, playing a role in sperm transport and production of testosterone by the testes. In the brain, oxytocin acts as a chemical messenger and has an important role in many human behaviors. Certain factors that are driving the market growth include the increasing prevalence of pregnancy complications, the rising number of births globally, and growing awareness of induced labor and breastfeeding.
However, stringent regulations and the high cost of oxytocin drugs are expected to be the key restraints for the oxytocin market growth. While oxytocin usage is widely approved to alleviate pain during childbirth by contracting the uterus, reports concerning its misuse have prompted governments to issue strict regulations for its usage. Excessive oxytocin levels may aggravate stress levels instead. Thus, governments are looking to restrict its usage through regulations, which is expected to act as a major restraint to its market growth.
The oxytocin market is segmented based on indication, distribution channel, and geography.
Despite prolific advancements in maternal healthcare, growing pregnancy complications have heightened maternal mortality rates in recent years. According to W.H.O, 94% of all maternal deaths occur in low- and middle-income countries, with adolescents aged 10-14 years being at maximum risk. About 295,000 women succumbed to childbirth-induced bleeding and other complications since 2017. The majority of these deaths occurred across 15 fragile states in Africa. Some leading causes of death include excessive bleeding, post-natal vaginal infection, and eclampsia. Besides administering drugs, major efforts are being undertaken to avoid unwanted pregnancies altogether, which included encouraging good contraceptive practices during sexual intercourse. Attributed to such high fatality rates, the production of synthetic oxytocin is increasing across the world, thus providing major traction to the market.
Impact of COVID – 19.
The COVID-19 pandemic has exerted significant pressure on the global healthcare industry, significantly disrupting treatment for non-communicable diseases. Potent challenges exist for disbursing effective reproductive, maternal, and contraceptive care respectively. Presently, the reallocation of healthcare resources has compelled pregnant women to deliver their babies in homecare settings, which poses several life-threatening risks to both mothers and children. Based on these developments, demand for oxytocin products is likely to remain sustained until the time the pandemic subsides, with manufacturers scrambling to augment their supply chains to cater to the rising demand for maternity care products in the short run.
February 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Ephedrine Sulfate Injection, USP, 50mg/mL, in the US, through its US affiliate, Hikma Pharmaceuticals USA Inc. to tackle the pressor effect caused by postpartum oxytocin use.
March 2019 – Janssen Pharmaceutica N.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that it has entered into a sponsored research agreement with the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University to advance the development of an inhaled version of oxytocin to help prevent and manage Post-Partum Hemorrhage (PPH).
Prominent/major key market players in the oxytocin market include Bimeda, Pfizer Inc, Taj Pharmaceuticals Ltd., and KAPL among others. The players in the Oxytocin market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players in the market have been covered along with their relative competitive strategies and the report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key distribution channels and services being offered along with the recent deals and investments of these important players in the oxytocin market.
|The market size value in 2019||US$25.242 million|
|The market size value in 2026||US$36.628 million|
|Growth Rate||CAGR of 5.46% from 2019 to 2026|
|Forecast Unit (Value)||USD Million|
|Segments covered||Indication, Distribution channel, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Bimeda, Pfizer Inc, Taj Pharmaceuticals Ltd., KAPL, Grindeks, Merck & Co, Roche, Mylan, GSK, JHP Pharmaceuticals|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What will be the oxytocin market size by 2026?
A1. The oxytocin market is expected to reach a market size of US$36.628 million by 2026.
Q2. What is the size of global oxytocin market?
A2. Oxytocin Market was valued at US$25.242 million in 2019.
Q3. What are the growth prospects for oxytocin market?
A3. The global oxytocin market is expected to grow at a CAGR of 5.46% during the forecast period.
Q4. What factors are anticipated to drive the oxytocin market growth?
A4. Certain factors that are driving the oxytocin market growth include the increasing prevalence of pregnancy complications, the rising number of births globally, and growing awareness of induced labor and breastfeeding.
Q5. Who are the major players in the oxytocin market?
A5. Prominent/major key market players in the oxytocin market include Bimeda, Pfizer Inc, Taj Pharmaceuticals Ltd., and KAPL among others.